Who makes Rilzabrutinib amorphous form?

Rilzabrutinib amorphous form is developed by Sanofi.

What development phase is Rilzabrutinib amorphous form in?

Rilzabrutinib amorphous form is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Rilzabrutinib amorphous form

Sanofi · Phase 1 active Small molecule

At a glance

Generic name	Rilzabrutinib amorphous form
Also known as	SAR444671
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rilzabrutinib amorphous form CI brief — competitive landscape report
Rilzabrutinib amorphous form updates RSS · CI watch RSS
Sanofi portfolio CI